TY  -  
T1  - Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study) 
SN  -  /  
UR  - http://hdl.handle.net/10138/303577 
T3  -  
A1  - PRINCIPAL Study Grp; Schmidinger, Manuela; Bamias, Aristotelis; Procopio, Giuseppe; Hawkins, Robert; Rodriguez Sanchez, Angel; Vazquez, Sergio; Srihari, Narayanan; Kalofonos, Haralabos; Bono, Petri; Pisal, Chaitali Babanrao; Hirschberg, Yulia; Dezzani, Luca; Ahmad, Qasim; Jonasch, Eric 
A2  -  
PB  -  
Y1  - 2019 
LA  - eng 
AB  - BackgroundReal-world data are essential to accurately assessing efficacy and toxicity of approved agents in everyday practice. PRINCIPAL, a prospective, observational study, was designed to confirm the real-world safety and efficacy of pazopanib in patients with advanced renal cell carcinoma (RCC). Subjects, Materials, and MethodsPatients with clear cell advanced/metastatic RCC and a clinical decision to initiate pazopanib treatment within 30days of enrollment were eligible. Primary objectives i... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - Renal cell carcinoma; Pazopanib; Real-world; Observational; Tyrosine kinase inhibitor; DOUBLE-BLIND; PHASE-III; SUNITINIB; SURVIVAL; EVEROLIMUS; 3122 Cancers 
N1  -   
PP  -  
ER  -